Published May 1, 2019 | Version v1
Journal article Metadata-only

Prognostic significance of metabolic parameters measured by 18F-FDG PET/CT in limited-stage small-cell lung carcinoma

Creators

  • 1. Seoul National University Bundang Hospital, Division of Hematology and Medical Oncology, Department of Internal Medicine (Korea, Republic of)
  • 2. Seoul National University Bundang Hospital, Department of Nuclear Medicine (Korea, Republic of)
  • 3. Seoul National University College of Medicine, Department of Internal Medicine (Korea, Republic of)

Description

Purpose

Metabolic parameters measured by [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) are important prognostic factors in several types of cancers. We evaluated the predictive value of tumor metabolic parameters measured by 18F-FDG PET/CT in limited-disease small-cell lung cancer (LD-SCLC).

Methods

This retrospective study included 30 LD-SCLC patients who underwent standard chemotherapy after radiotherapy with 18F-FDG PET/CT. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and blood glucose-corrected values were used to evaluate metabolic parameters in primary tumors.

Results

For the median follow-up of 41.1 months, median overall survival (OS) was 75.0 months [95% confidence interval (CI) 20.9–129.1 months], and median progression-free survival (PFS) was 9.5 months (95% CI 6.8–12.1 months). Two-year OS was 78.6%, and PFS was 32.7%. OS analysis indicated that MTV and TLG were significant predictors of OS following standard treatment. High glucose-corrected SUVmax (glu-SUVmax) was related to shorter median PFS. On multivariate analysis, MTV was an independent factor of OS, and glu-SUVmax was significantly related to PFS.

Conclusions

MTV and glu-SUVmax measured on pretreatment 18F-FDG PET/CT were independent prognostic factors for LD-SCLC patients after chemoradiotherapy with curative intent. These metabolic markers need validation in larger prospective studies but may be useful in the clinical care of LD-SCLC patients.

Additional details

Identifiers

DOI
10.1007/s00432-019-02848-9;

Publishing Information

Journal Title
Journal of Cancer Research and Clinical Oncology
Journal Volume
145
Journal Issue
5
Journal Page Range
p. 1361-1367
ISSN
0171-5216
CODEN
JCROD7

INIS

Country of Publication
Germany
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
54072736
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BLOOD; CARCINOMAS; CHEMOTHERAPY; COMBINED THERAPY; FLUORINE 18; FLUORODEOXYGLUCOSE; GLUCOSE; GLYCOLYSIS; LUNGS; MULTIVARIATE ANALYSIS; PATIENTS; POSITRON COMPUTED TOMOGRAPHY; RADIOTHERAPY; VALIDATION
Descriptors DEC
ALDEHYDES; ANTIMETABOLITES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BIOLOGICAL MATERIALS; BODY; BODY FLUIDS; CARBOHYDRATES; CHEMICAL REACTIONS; COMPUTERIZED TOMOGRAPHY; DECOMPOSITION; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; FLUORINE ISOTOPES; HEXOSES; HOURS LIVING RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LIGHT NUCLEI; MATERIALS; MATHEMATICS; MEDICINE; METABOLISM; MONOSACCHARIDES; NANOSECONDS LIVING RADIOISOTOPES; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; ODD-ODD NUCLEI; ORGANIC COMPOUNDS; ORGANS; RADIOISOTOPES; RADIOLOGY; RESPIRATORY SYSTEM; SACCHARIDES; STATISTICS; TESTING; THERAPY; TOMOGRAPHY

Optional Information

Copyright
Copyright (c) 2019 Springer-Verlag GmbH Germany, part of Springer Nature